MRNA logo
MRNA
Moderna

Inflated Valuation Will Choke Revenue Amid Tighter Global Scrutiny

Published
14 Apr 25
Updated
09 Aug 25
AnalystLowTarget's Fair Value
US$18.00
48.3% overvalued intrinsic discount
09 Aug
US$26.69
Loading
1Y
-69.2%
7D
0.3%

Author's Valuation

US$18.0

48.3% overvalued intrinsic discount

AnalystLowTarget Fair Value

Narrative
Updates3

Shared on07 May 25
Fair value Decreased 7.55%

Read more

Shared on30 Apr 25
Fair value Decreased 2.65%

AnalystLowTarget made no meaningful changes to valuation assumptions.

Read more

Shared on23 Apr 25
Fair value Decreased 20%

Read more